Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oramed Pharmaceuticals has released results of a Phase IIa clinical trial of its ORMD-0801, an oral insulin capsule for the treatment of type 2 diabetes.
Subscribe to our email newsletter
The trial was carried out under a US Food and Drug Administration (FDA) IND (Investigational New Drug) protocol, and it met all primary and secondary endpoints.
A total of 30 patients with type 2 diabetes participated in the trial in an in-patient setting for one week.
In the trial, endpoints of safety as well as pharmacodynamic and pharmacokinetic effects were evaluated against a placebo control.
Oramed CEO Nadav Kidron said the company is happy with the results which give a solid validation for its platform technology in general and its oral insulin program in particular.
"Following on the results from this type 2 diabetes study we are gearing up to start a multi-center Phase 2b study later this year," Kidron said.
"We are also excited about the potential of this drug for type 1 diabetes and plan to initiate a Phase 2a FDA study for this indication in the near term."
ORMD-0801 is an orally ingestible insulin capsule for the early stages of type 2 diabetes, when it can still slow the rate of degeneration of the disease by providing additional insulin to the body and allowing pancreatic respite.